Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis
Yoshinori Okuda,1 Seitaro Omoto,2 Takehito Taniura,3 Akira Shouzu,4 Shosaku Nomura,51Division of Internal Medicine, Meisei Memorial Hospital, 2Division of Internal Medicine, Kohrigaoka Yukeikai Hospital, 3Division of Internal Medicine, Daiwa Hospital, 4Division of Internal Medicine, Saiseikai Izuo H...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-04-01
|
Series: | International Journal of General Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/effects-of-teneligliptin-on-pdmps-and-pai-1-in-patients-with-diabetes--peer-reviewed-article-IJGM |
id |
doaj-967bcee0180e41eb87ebc3ff481b80ef |
---|---|
record_format |
Article |
spelling |
doaj-967bcee0180e41eb87ebc3ff481b80ef2020-11-24T23:11:21ZengDove Medical PressInternational Journal of General Medicine1178-70742016-04-012016Issue 1657126407Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysisOkuda YOmoto STaniura TShouzu ANomura SYoshinori Okuda,1 Seitaro Omoto,2 Takehito Taniura,3 Akira Shouzu,4 Shosaku Nomura,51Division of Internal Medicine, Meisei Memorial Hospital, 2Division of Internal Medicine, Kohrigaoka Yukeikai Hospital, 3Division of Internal Medicine, Daiwa Hospital, 4Division of Internal Medicine, Saiseikai Izuo Hospital, 5First Department of Internal Medicine, Kansai Medical University, Osaka, Japan Background: Cardiovascular disease (CVD) is the main cause of death among hemodialysis (HD) patients. The effects of the dipeptidyl peptidase-4 inhibitor teneligliptin on CVD-related biomarkers in patients with type 2 diabetes mellitus (T2DM) receiving HD treatment are poorly understood. To determine whether teneligliptin has anti-CVD properties, we assessed its effects on soluble P-selectin (sP-selectin), platelet-derived microparticles (PDMPs), plasminogen activator inhibitor 1 (PAI-1), soluble E-selectin (sE-selectin), soluble vascular adhesion molecule 1 (sVCAM-1), and adiponectin plasma levels in HD and non-HD patients with T2DM. Methods: Patients with T2DM eligible for teneligliptin monotherapy or combination therapy (eg, teneligliptin plus a sulfonylurea) were administered teneligliptin (20 mg/d) once daily for 6 months. Plasma levels of sP-selectin, PDMPs, PAI-1, sE-selectin, sVCAM-1, and adiponectin were measured by enzyme-linked immunosorbent assay at baseline and after 3 months and 6 months of treatment. Results: Teneligliptin therapy significantly reduced plasma levels of sP-selectin, PDMPs, and PAI-1 compared with baseline levels, while significantly increasing adiponectin levels. sE-selectin and sVCAM-1 levels were significantly decreased only at 6 months. The reduction in sP-selectin, PDMPs, and PAI-1 was more significant in HD patients than in non-HD patients. However, the improvement in adiponectin levels was unchanged with HD treatment. Conclusion: By modulating PDMPs or PAI-1, teneligliptin shows an antiatherothrombotic effect that may be beneficial in the primary prevention of CVD in patients with T2DM on HD.Keywords: type 2 diabetes mellitus, teneligliptin, hemodialysis, PDMP, PAI-1 https://www.dovepress.com/effects-of-teneligliptin-on-pdmps-and-pai-1-in-patients-with-diabetes--peer-reviewed-article-IJGMtype 2 diabetes mellitusteneligliptinhemodialysisPDMPPAI-1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Okuda Y Omoto S Taniura T Shouzu A Nomura S |
spellingShingle |
Okuda Y Omoto S Taniura T Shouzu A Nomura S Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis International Journal of General Medicine type 2 diabetes mellitus teneligliptin hemodialysis PDMP PAI-1 |
author_facet |
Okuda Y Omoto S Taniura T Shouzu A Nomura S |
author_sort |
Okuda Y |
title |
Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis |
title_short |
Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis |
title_full |
Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis |
title_fullStr |
Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis |
title_full_unstemmed |
Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis |
title_sort |
effects of teneligliptin on pdmps and pai-1 in patients with diabetes on hemodialysis |
publisher |
Dove Medical Press |
series |
International Journal of General Medicine |
issn |
1178-7074 |
publishDate |
2016-04-01 |
description |
Yoshinori Okuda,1 Seitaro Omoto,2 Takehito Taniura,3 Akira Shouzu,4 Shosaku Nomura,51Division of Internal Medicine, Meisei Memorial Hospital, 2Division of Internal Medicine, Kohrigaoka Yukeikai Hospital, 3Division of Internal Medicine, Daiwa Hospital, 4Division of Internal Medicine, Saiseikai Izuo Hospital, 5First Department of Internal Medicine, Kansai Medical University, Osaka, Japan Background: Cardiovascular disease (CVD) is the main cause of death among hemodialysis (HD) patients. The effects of the dipeptidyl peptidase-4 inhibitor teneligliptin on CVD-related biomarkers in patients with type 2 diabetes mellitus (T2DM) receiving HD treatment are poorly understood. To determine whether teneligliptin has anti-CVD properties, we assessed its effects on soluble P-selectin (sP-selectin), platelet-derived microparticles (PDMPs), plasminogen activator inhibitor 1 (PAI-1), soluble E-selectin (sE-selectin), soluble vascular adhesion molecule 1 (sVCAM-1), and adiponectin plasma levels in HD and non-HD patients with T2DM. Methods: Patients with T2DM eligible for teneligliptin monotherapy or combination therapy (eg, teneligliptin plus a sulfonylurea) were administered teneligliptin (20 mg/d) once daily for 6 months. Plasma levels of sP-selectin, PDMPs, PAI-1, sE-selectin, sVCAM-1, and adiponectin were measured by enzyme-linked immunosorbent assay at baseline and after 3 months and 6 months of treatment. Results: Teneligliptin therapy significantly reduced plasma levels of sP-selectin, PDMPs, and PAI-1 compared with baseline levels, while significantly increasing adiponectin levels. sE-selectin and sVCAM-1 levels were significantly decreased only at 6 months. The reduction in sP-selectin, PDMPs, and PAI-1 was more significant in HD patients than in non-HD patients. However, the improvement in adiponectin levels was unchanged with HD treatment. Conclusion: By modulating PDMPs or PAI-1, teneligliptin shows an antiatherothrombotic effect that may be beneficial in the primary prevention of CVD in patients with T2DM on HD.Keywords: type 2 diabetes mellitus, teneligliptin, hemodialysis, PDMP, PAI-1 |
topic |
type 2 diabetes mellitus teneligliptin hemodialysis PDMP PAI-1 |
url |
https://www.dovepress.com/effects-of-teneligliptin-on-pdmps-and-pai-1-in-patients-with-diabetes--peer-reviewed-article-IJGM |
work_keys_str_mv |
AT okuday effectsofteneligliptinonpdmpsandpai1inpatientswithdiabetesonhemodialysis AT omotos effectsofteneligliptinonpdmpsandpai1inpatientswithdiabetesonhemodialysis AT taniurat effectsofteneligliptinonpdmpsandpai1inpatientswithdiabetesonhemodialysis AT shouzua effectsofteneligliptinonpdmpsandpai1inpatientswithdiabetesonhemodialysis AT nomuras effectsofteneligliptinonpdmpsandpai1inpatientswithdiabetesonhemodialysis |
_version_ |
1725604852537491456 |